Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma

American Journal of Surgical Pathology

Volumn 27, Issue 7, 2003, Pages 1013-1019

  Chott, Andreas ^a,e   Guenther, Philipp ^b   Huebner, Angela ^b   Selzer, Edgar ^a   Parwaresch, Reza M ^c   Horny, Hans Peter ^d   Valent, Peter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C KIT; CD 117; Mast cell sarcoma; Mast cells; Mastocytosis; Tryptase

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTIC ACID; CD45 ANTIGEN; CD68 ANTIGEN; COMPLEMENT COMPONENT C5A RECEPTOR; MICROSOMAL AMINOPEPTIDASE; STEM CELL FACTOR RECEPTOR; TOLONIUM CHLORIDE; TRYPTASE; VALINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CELL STRUCTURE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MAST CELL; MASTOCYTOSIS; PARAMETER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; SCHOOL CHILD;

ANTIGENS, CD; ANTIGENS, SURFACE; ASPARTIC ACID; BRAIN NEOPLASMS; CELL NUCLEUS; CHILD; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MAST CELLS; MAST-CELL SARCOMA; PHENOTYPE; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SERINE ENDOPEPTIDASES; TRYPTASES; TUMOR MARKERS, BIOLOGICAL; VALINE;

EID: 0038001490     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200307000-00019     Document Type: Article

References (42)

1. Agis H, Willheim M, Sperr WR, et al. Monocytes do not make mast cells when cultured in the presence of SCF: characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J Immunol 1993;151:4221-7.
2. Butterfield JH, Weiler D, Diewald G, et al. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988;12:345-55.
3. Chott A, Vesely M, SimonitSch I, et al. Classification of intestinal T-cell neoplasms and their differential diagnosis. Am J Clin Pathol 1999;111(suppl 1):68-74.
4. Dalton R, Chan L, Batten E, et al. Mast cell leukemia: evidence for bone marrow origin of the pathologic clone. Br J Haematol 1986;64:397-406.
5. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998;91:2731-6.
6. Escribano L, Diaz-Augustin B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001;25:563-70.
7. Escribano L, Orfao A, Villarrubia J, et al. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry 1997;30:98-102.
8. Füreder W, Agis H, Willheim M, et al. Differential expression of complement receptors on human mast cells and basophils; evidence for mast cell heterogeneity and C5aR/CD88 expression on skin mast cells. J Immunol 1995;155:3152-60.
9. Fukuda T, Kamishima T, Tsuura Y, et al. Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil/mast cell precursors from chronic myelogenous leukaemia. J Pathol 1995;177:139-46.
10. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest 1993;92:1736-44.
11. Gabriel LC, Escribano LM, Navarro JL. Human bone marrow mast cells in systemic mast cell disease: ultrastructure and evaluation of fixation and staining techniques. Allergy 1988;43:430-4.
12. Ghannadan M, Baghestanian M, Wimazal F, et al. Phenotypic characterization of human skin mast cells by combined staining for toluidine blue and CD antibodies. J Invest Dermatol 1998;111:689-95.
13. Guenther PP, Huebner A, Sobottka SB, et al. Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol 2001;23:134-8.
14. Horny H-P, Parwaresch MR, Kaiserling E, et al. Mast cell sarcoma of the larynx. J Clin Pathol 1986;39:596-602.
15. Horny H-P, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22:1132-40.
16. Horny H-P, Ruck P, Xiao J-C, et al. Immunoreactivity of normal and neoplastic human tissue mast cells with macrophage-associated antibodies, with special reference to the recently developed monoclonal antibody PG-M1. Hum Pathol 1993;24:355-8.
17. Jordan JH, Sperr WR, Lechner K, et al. Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to novel SM-criteria. Leuk Lymphoma 2002;43:575-82.
18. Jordan H, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/KIT, and bcl-xL. Hum Pathol 2001;32:545-52.
19. Kiener H, Baghestanian M, Dominkus M, et al. Expression of C5a-receptor (CD88) on synovial mast cells in rheumatoid arthritis. Arthritis Rheum 1998;41:233-45.
20. Kirshenbaum AS, Goff JP, Semere T, et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-KIT+, and expresses aminopeptidase N (CD13). Blood 1999;94:2333-42.
21. Kirshenbaum AS, Goff JP, Kessler SW, et al. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992;148:772-7.
22. Klatt EC, Lukes RJ, Meyer PR. Benign and malignant mast cell proliferations: diagnosis and separation using a pH-dependent toluidine blue stain in tissue sections. Cancer 1983;51:1119-24.
23. Kojima M, Nakamura S, Itoh H, et al. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol 1999;12:739-43.
24. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology 1979;3:349-65.
25. Li WV, Kapadia SB, Sonmez-Alpan E, et al. Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Mod Pathol 1996;9:982-8.
26. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-4.
27. Longley BJ, Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct forms of human mastocytosis. Proc Natl Acad Sci USA 1999;96:1609-14.
28. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995;92:10560-4.
29. Ochi H, Hirani WM, Yuan Q, et al. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J Exp Med 1999;190:267-80.
30. Parwaresch MR, Horny H-P, Lennert K. Tissue mast cells in health and disease. Pathol Res Pract 1985;179:439-61.
31. Rottem M, Okada T, Goff JP, et al. Mast cells cultured from peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/FcεRI- cell population. Blood 1994;84:2489-96.
32. Schernthaner GH, Jordan JH, Agis H, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001;98:3784-92.
33. Schwartz LB, Sakai K, Bradford TR, et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995;96:2702-10.
34. Shimizu Y, Sakai K, Miura T, et al. Characterization of 'adult-type' mast cells derived from human bone marrow CD34+ cells cultured in the presence of stem cell factor and interleukin-6: interleukin-4 is not required for constitutive expression of CD54, Fc epsilon RI alpha and chymase, and CD13 expression is reduced during differentiation. Clin Exp Allergy 2002;32:872-80.
35. Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytologic grading of mastocytosis. Leuk Res 2001;25:529-36.
36. Valent P, Horny H-P, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25.
37. Valent P, Ashman LK, Hinterberger W, et al. Mast cell typing: demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 1998;73:1778-85.
38. Valent P. Mast cell differentiation antigens: expression in normal and malignant cells and use for diagnostic purposes. Eur J Clin Invest 1995;25:715-20.
39. Valent P, Schernthaner GH, Sperr WR, et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev 2001;179:74-81.
40. Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells. Adv Immunol 1992;52:333-23.
41. Valent P, Horny H-P, Li CY, et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, et al., eds. World Health Organization Classification of Tumors, Pathology and Genetics: Tumors of Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001:293-302.
42. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-51.